---
title: Bioavailability of ABT-450 and ABT-267 With Ritonavir
nct_id: NCT02052362
overall_status: COMPLETED
phase: PHASE1
sponsor: AbbVie
study_type: INTERVENTIONAL
primary_condition: Absolute Bioavailability
countries: United Kingdom
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02052362.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02052362"
ct_last_update_post_date: 2014-02-19
last_seen_at: "2026-05-12T07:00:48.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Bioavailability of ABT-450 and ABT-267 With Ritonavir

**Official Title:** A Phase I, Open-Label, Single Centre Study Designed to Determine the Absolute Bioavailability of ABT-450 (150 mg) and ABT-267 (25 mg) When Administered as an Oral Co-Formulated Product With Ritonavir (100 mg), ABT 450/r/ABT 267, to Healthy Adult Subjects

**NCT ID:** [NCT02052362](https://clinicaltrials.gov/study/NCT02052362)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 16
- **Lead Sponsor:** AbbVie
- **Conditions:** Absolute Bioavailability
- **Start Date:** 2014-01
- **Completion Date:** 2014-02
- **CT.gov Last Update:** 2014-02-19

## Brief Summary

A study to investigate the fraction of ABT-267 and ABT-450 absorbed by the body when given in combination with each other and Ritonavir(r).

## Detailed Description

Absolute bioavailability of ABT-267 and ABT-450 in the body when given together

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

1. Healthy males or non-pregnant, non-lactating healthy females
2. Body mass index of 18.0 to 30.0 kg/m2
3. Must be willing and able to communicate and participate in the whole study
4. Must provide written informed consent
5. Must agree to use an adequate method of contraception
6. In a condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG

Exclusion Criteria:

1. Participation in a clinical research study within the previous 3 months or in an absorption, distribution, metabolism, and excretion (ADME) study within the previous 12 months
2. History of any drug or alcohol abuse in the past 2 years or current smokers and those who have smoked within the last 12 months or a positive cotinine urine test at screening and admission
3. Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study
4. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results
5. Donation or loss of greater than 550 mL of blood (including plasmapheresis) or receipt of a transfusion of any blood product within the previous 8 weeks
6. Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies within the 14 days or any drug by injection (including vaccines) within 30 days or within 10 half-lives of the respective medication, whichever is longer, before Investigational Medical Product (IMP) administration
```

## Arms

- **Group 1 - Regimen A** (EXPERIMENTAL) — 8 Subjects in Group I - Regimen A: ABT-450/r/ABT-267
- **Group 2 - Regimen B** (EXPERIMENTAL) — 8 Subjects in Group II - Regimen B: ABT-450/r/ABT-267

## Interventions

- **ABT-450/r/ABT-267** (DRUG) — ABT-450, ABT-267 and ritonavir

## Primary Outcomes

- **Absolute bioavailability** _(time frame: Day 1 until 72 hours after single dose of ABT-450/r/ABT-267)_ — dose normalized AUC(0-inf) for oral dose/dose normalized AUC(0-inf) for IV dose

## Secondary Outcomes

- **Safety Labs** _(time frame: Day -1 until 72 hours after single dose of ABT-450/r/ABT-267)_
- **Electrocardiograms (ECGs)** _(time frame: Day-1 until 24 hours after single dose of ABT-450/r/ABT-267)_
- **Number of participants with adverse events** _(time frame: Screening until 7 days after single dose of ABT-450/r/ABT-267)_
- **Physical Exam** _(time frame: Day-1 until 72 hours after single dose ABT-450/r/ABT-267)_

## Locations (1)

- Site Reference ID/Investigator# 118615, Nottingham, United Kingdom

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.site reference id/investigator# 118615|nottingham||united kingdom` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02052362.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02052362*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*